Category: Healthcare & Life Sciences
-
Big pharma has spent 2026 buying clinical-stage biotechs to refill aging pipelines. The latest wave of deals is going after the manufacturing infrastructure instead.
Read More: Pharma’s Pipeline Refill Extends to the Plumbing200 words–
1–2 minutes
All Categories
- Aerospace & Defense
- Capital Markets & IPO
- Consumer & Retail
- Debt Capital Markets
- Featured Deals
- Financial Services
- Financial Sponsors & M&A
- Healthcare
- Healthcare & Life Sciences
- Industrials
- M&A Advisory
- Macro & Monetary Policy
- Power & Energy
- Private Credit
- Regulatory & Compliance
- Restructuring
- Sustainable Finance
- Technology & AI
- Wealth Management